A recent study demonstrated that neoadjuvant immunochemotherapy in early‐stage lung cancer with EGFR mutations resulted in a major pathological remission rate of 44%, significantly surpassing the efficacy observed in historical controls treated with EGFR‐TKIs [66]. The gene discussed is EGFR; the disease is lung carcinoma.